Vaccine side effects in Florida
State Surgeon General
Critical that as public health professionals,
responses are adapted to the present,
to chart a future guided by data.
Substantial increase in Vaccine Adverse Event Reporting System (VAERS) reports,
from Florida after the COVID-19 vaccine rollout.
Overall reports submitted to VAERS, Florida 2006–2022
1,700% increase in VAERS reports
Compared to an increase of 400% in overall vaccine administration
Reporting of life-threatening conditions
Increased over 4,400%
This is a novel increase
Not seen during the 2009 H1N1 vaccination campaign
There is a need for additional unbiased research,
to better understand the COVID-19 vaccines' short and long-term effects.
The findings in Florida are consistent with various studies that continue to uncover such risks.
Letter from Dr Joseph A. Ladapo
To U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC)
illustrating the risk factors associated with the mRNA COVID-19 vaccines,
and emphasizing the need for additional transparency
Studies cited by Florida report
Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults
mRNA COVID-19 vaccines were associated with an excess risk of serious adverse events,
including coagulation disorders,
acute cardiac injuries,
This risk was 1 in 550 individuals,
which is much higher than other vaccines.
The excess risk of serious adverse events found in our study points to the need for formal harm-benefit analyses,
particularly those that are stratified according to risk of serious COVID-19 outcomes.
These analyses will require public release of participant level datasets.
Increased emergency cardiovascular events among under-40 population in Israel during vaccine rollout and third COVID-19 wave
increased acute cardiac arrests and other acute cardiac events following mRNA COVID-19 vaccination.
An increase of over 25% was detected
volume of cardiac arrest and acute coronary syndrome EMS calls in the 16-39-year-old (January to May 2021)
Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries
assessed the risk of thromboembolic and thrombocytopenic events related to COVID-19 vaccines,
and found preliminary evidence of increased risk of both coronary disease and cardiovascular disease.
265 339 hospital contacts
In the 28-day period following vaccination, there was an increased rate of coronary artery disease following mRNA-1273 (Moderna) vaccination
Increased rate of coagulation
(following all 3 vaccines)
AZD1222: RR, 2.01
BNT162b2: RR, 1.12
mRNA-1273: RR, 1.26
Increased risk of cerebrovascular disease
AZD1222: RR, 1.32
BNT162b2: RR, 1.09
mRNA-1273: RR, 1.21
To support transparency, the State of Florida reminds health care providers to accurately communicate the risks and benefits of all clinical interventions to their patients, including those associated with the COVID-19 vaccine as additional risks continue to be identified and disclosed to the public.
About the Florida Department of Health
The department, nationally accredited by the Public Health Accreditation Board, works to protect, promote and improve the health of all people in Florida through integrated state, county and community efforts.
Follow us on Twitter at @HealthyFla and on Facebook. For more information about the Florida Department of Health please visit www.FloridaHealth.gov.